Risk of thrombosis and mortality in inflammatory bowel disease
Carregando...
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Citação
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, v.9, article ID 142, 7p, 2018
Resumo
Objectives: Patients with inflammatory bowel disease have a higher risk of thrombosis, which is associated with a higher morbidity and mortality. Most data about VTE are related to hospitalized patients with active disease, but several cases happen in the outpatient setting, and are not covered by current prophylaxis recommendation. As the knowledge of VTE in outpatients is still poor, the aim of this study is to evaluate the risk, clinical data and mortality of thrombosis in patients followed in our center, comparing our findings with the current prophylaxis recommendation. Methods: The medical electronic chart of 1093 inflammatory bowel disease patients and their image exams were actively searched for words related to thrombosis, followed by charts reviewed to collect information about the event and data regarding clinical settings and thrombosis profile. Results: Overall, 654 Crohn's and 439 Colitis patients were included. Thrombosis prevalence was 5.1%, and mortality rate was higher in patients who had suffered thrombosis (10.71% vs. 1.45%, OR 8.0). Half of them developed thrombosis in the outpatient setting, 52% of these had disease activity, 17% had recent hospitalization, and 10% had previous thrombosis. In 27% of cases, diagnosis was done by routine image exams, with no clinical symptoms or previous history of thrombosis. None of them had used thromboprophylaxis. However, a great majority of patients who had thrombosis during hospitalization used heparin prophylaxis. Conclusion: Inflammatory bowel disease patients who develop thrombosis have an increased mortality risk. A significant proportion of the events happened in patients without a clear thromboprophylaxis recommendation or in those receiving heparin prophylaxis.
Palavras-chave
Referências
- Bollen L, 2016, EUR J GASTROEN HEPAT, V28, P1, DOI 10.1097/MEG.0000000000000495
- Di Fabio F, 2011, SEMIN THROMB HEMOST, V37, P220, DOI 10.1055/s-0031-1273086
- Fumery M, 2014, J CROHNS COLITIS, V8, P469, DOI 10.1016/j.crohns.2013.09.021
- Gionchetti P, 2017, J CROHNS COLITIS, V11, P135, DOI 10.1093/ecco-jcc/jjw169
- Grainge MJ, 2010, LANCET, V375, P657, DOI 10.1016/S0140-6736(09)61963-2
- Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y
- Higaki S, 2006, J GASTROEN HEPATOL, V21, P1407, DOI 10.1111/j.1440-1746.2006.04319.x
- Irving PM, 2005, CLIN GASTROENTEROL H, V3, P617, DOI 10.1053/S1542-3565(05)00154-0
- Kohoutova D, 2015, J THROMB THROMBOLYS, V39, P489, DOI 10.1007/s11239-014-1129-7
- LaMori JC, 2015, CLIN THER, V37, P62, DOI 10.1016/j.clinthera.2014.10.024
- Nguyen GC, 2008, AM J GASTROENTEROL, V103, P2272, DOI 10.1111/j.1572-0241.2008.02052.x
- Nguyen GC, 2014, GASTROENTEROLOGY, V146, P835, DOI 10.1053/j.gastro.2014.01.042
- Novacek G, 2010, GASTROENTEROLOGY, V139, P779, DOI 10.1053/j.gastro.2010.05.026
- Sam JJ, 2013, DIGEST DIS SCI, V58, P46, DOI 10.1007/s10620-012-2435-6
- Scoville EA, 2014, INFLAMM BOWEL DIS, V20, P631, DOI 10.1097/MIB.0000000000000007
- Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401